Clinical Trial Update: LBH589 (Panobinostat) for the Treatment of Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 clinical trial update for LBH589 (panobinostat) in myelofibrosis with current status not reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Polycythemia Vera
• Post-essential Thrombocythemia-related Myelofibrosis
• Post-polycythemia Myelofibrosis

Drugs mentioned

• Farydak (panobinostat) (panobinostat)

Snippet

Sponsor: Ronald Hoffman | Conditions: Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Phase 1, Phase 2 | Status: UNKNOWN